Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Agnese Paderi, Roberta Giorgione, Elisa Giommoni, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 860-860
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 721
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
Yee-Ming Melody Cheung, Wei Wang, Bradley A. McGregor, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 8, pp. 1795-1812
Open Access | Times Cited: 56
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Betul Ibis, Konstantinos Aliazis, Carol Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 39
Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
Xinyue Han, Yingcui Chen, Hong Xie, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Megan L. Baker, Yu Yamamoto, Mark A. Perazella, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004421-e004421
Open Access | Times Cited: 30
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
Yaxin Du, Wenjie Wu, Mei Chen, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 10, pp. 1093-1093
Open Access | Times Cited: 15
Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment
Guodong Liao, Ping Wang, Yuyong Wang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 31
Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
Agnese Paderi, Elisabetta Gambale, Cristina Botteri, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 5789-5789
Open Access | Times Cited: 30
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Dylan J. Martini, Subir Goyal, Yuan Liu, et al.
The Oncologist (2021) Vol. 26, Iss. 10, pp. e1742-e1750
Open Access | Times Cited: 28
Systemic Sclerosis Association with Malignancy
Gemma Lepri, Martina Catalano, Silvia Bellando-Randone, et al.
Clinical Reviews in Allergy & Immunology (2022) Vol. 63, Iss. 3, pp. 398-416
Open Access | Times Cited: 21
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Yuan Gao, Caixia Wu, Xueqi Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
Satoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.
International Journal of Clinical Oncology (2023) Vol. 28, Iss. 12, pp. 1651-1658
Open Access | Times Cited: 12
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Abushukair, Biagio Ricciuti, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 4
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Yaowen Zhang, Junru Chen, Haoyang Liu, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102787-102787
Closed Access | Times Cited: 3
Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization
Liuliu Quan, Jinsong Liu, Yuxin Wang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Calogera Claudia Spagnolo, G Giuffrida, Salvatore Cannavò, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 246-246
Open Access | Times Cited: 15
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
Elisa Giommoni, Roberta Giorgione, Agnese Paderi, et al.
Immuno (2021) Vol. 1, Iss. 3, pp. 253-263
Open Access | Times Cited: 16
Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab
Kousuke Ueda, Shigetaka Suekane, Hirofumi Kurose, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 52, Iss. 5, pp. 479-485
Closed Access | Times Cited: 12
Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
Yanna Lei, Xiufeng Zheng, Qian Huang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials
Daniele Robesti, Luigi Nocera, Federico Belladelli, et al.
BJU International (2023) Vol. 133, Iss. 2, pp. 158-168
Closed Access | Times Cited: 5
C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients
Elisa Kankkunen, Patrick Penttilä, Katriina Peltola, et al.
Acta Oncologica (2022) Vol. 61, Iss. 10, pp. 1240-1247
Closed Access | Times Cited: 8
Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature
Christopher Hino, Kevin Nishino, Bryan Pham, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
Wenru Qin, Linlin Yang, Bingjie Fan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance
Hirotsugu Uemura, Nobuo Shinohara, Yoshihiko Tomita, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 53, Iss. 8, pp. 730-737
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top